A hyperbranched polymer includes a hyperbranched, hydrophobic molecular core, respective low molecular weight polyethyleneimine chains attached to at least three branches of the hyperbranched, hydrophobic molecular core, and respective polyethylene glycol chains attached to at least two other branches of the hyperbranched, hydrophobic molecular core. Examples of the hyperbranched polymer may be used to form hyperbranched polyplexes, and may be included in DNA or RNA delivery systems.

A hyperbranched polymer includes a hyperbranched, hydrophobic molecular core, respective low molecular weight polyethyleneimine chains attached to at least three branches of the hyperbranched, hydrophobic molecular core, and respective polyethylene glycol chains attached to at least two other branches of the hyperbranched, hydrophobic molecular core. Examples of the hyperbranched polymer may be used to form hyperbranched polyplexes, and may be included in DNA or RNA delivery systems.

Process for preparing copolyesters by introducing TPA, EG, and CHDM at an EG:TPA molar ratio of 2.3:1 to 2.7:1 into a reaction zone; reacting TPA with EG and CHDM at a temperature of at least 250° C. and pressure of up to 40 psi to form a first esterification product; passing the first esterification product to a reaction zone; esterifying the first esterification product at a temperature of at least 250° C. and pressure of up to 20 psi to form a second esterification product, passing the second esterification product to a reaction zone; polycondensing the second esterification product in the presence of a catalyst to form a prepolymerization product; passing the prepolymerization product to one or more reaction zones; and polycondensing the prepolymerization product in the presence of the catalyst to form a copolyester comprising 1.0 wt % or less of DEG, without requiring the use of DEG-suppressing additives.

Process for preparing copolyesters by introducing TPA, EG, and CHDM at an EG:TPA molar ratio of 2.3:1 to 2.7:1 into a reaction zone; reacting TPA with EG and CHDM at a temperature of at least 250° C. and pressure of up to 40 psi to form a first esterification product; passing the first esterification product to a reaction zone; esterifying the first esterification product at a temperature of at least 250° C. and pressure of up to 20 psi to form a second esterification product, passing the second esterification product to a reaction zone; polycondensing the second esterification product in the presence of a catalyst to form a prepolymerization product; passing the prepolymerization product to one or more reaction zones; and polycondensing the prepolymerization product in the presence of the catalyst to form a copolyester comprising 1.0 wt % or less of DEG, without requiring the use of DEG-suppressing additives.

Poly(amine-co-ester) polymers, methods of forming active agent-load polyplexes and particles therefrom, and methods of using them for delivery of nucleic acid agents with optimal uptake have been developed. Examples demonstrate critical molecular weights in combination with exposed carboxylic and/or hydroxyl groups, and methods of making. Typically, the compositions are less toxic, more efficient at drug delivery, or a combination thereof compared to a control other transfection reagents. In some embodiments, the compositions are suitable for in vivo delivery, and can be administered systemically to a subject to treat a disease or condition. For poly(amine-co-ester) polymers with specific amine or hydroxyl group containing end-groups in admixture with PEGylated poly(amine-co-ester) polymers, in vivo delivery to the lung by inhalation has been shown.

The present disclosure provides copolymers useful in medical devices. For example, the disclosure provides copolymers comprising the polymerization product ester block, ether blocks and diisocyanates. In certain embodiments, the disclosure provides a medical copolymer for implantation comprising ester blocks and ether blocks, wherein: the ester blocks comprise a negative free energy transfer and the ether blocks comprise a positive free energy transfer, the ether and ester blocks are less than 1/10 the length of said copolymer, and, the blocks are distributed such that no domain of contiguous blocks possessing the same polarity of free energy transfer are less than ⅓ of the molecular weight of the copolymer. The disclosure further provides methods of making the aforementioned polymers, and medical devices comprising the polymers.

The present disclosure provides copolymers useful in medical devices. For example, the disclosure provides copolymers comprising the polymerization product ester block, ether blocks and diisocyanates. In certain embodiments, the disclosure provides a medical copolymer for implantation comprising ester blocks and ether blocks, wherein: the ester blocks comprise a negative free energy transfer and the ether blocks comprise a positive free energy transfer, the ether and ester blocks are less than 1/10 the length of said copolymer, and, the blocks are distributed such that no domain of contiguous blocks possessing the same polarity of free energy transfer are less than ⅓ of the molecular weight of the copolymer. The disclosure further provides methods of making the aforementioned polymers, and medical devices comprising the polymers.

The present invention relates to novel high-value polycarbonate polyols, to processes for the production thereof, to polyisocyanate prepolymers obtainable therefrom and also polyurethane (PUR) and polyurethane urea elastomers which under particularly demanding applications show unique combinations of processing characteristics, hydrolysis and oxidation stability, mechanical and dynamic mechanical properties.

A biodegradable drug delivery compositions comprising a triblock copolymer containing a polyester and a polyethylene glycol and a diblock copolymer containing a polyester and an end-capped polyethylene glycol, as well as a pharmaceutically active principle is disclosed.

A biodegradable drug delivery compositions comprising a triblock copolymer containing a polyester and a polyethylene glycol and a diblock copolymer containing a polyester and an end-capped polyethylene glycol, as well as a pharmaceutically active principle is disclosed.